Impact of novel treatment options on long-term outcomes in CLL and WM

William Wierda, MD Anderson Cancer Center, Houston, US, discusses the impact of novel treatment options on long-term outcomes in chronic lymphocytic leukemia (CLL). He discusses the new standard-of-care of small molecule inhibitor monotherapy, and/or with a CD20 antibody. He also mentions the exciting data on combination approaches utilizing BCL-2 inhibitors with BTK inhibitors which have been shown to induce very good deep remissions in the majority of patients, so much so that it may be possible to consider discontinuing therapy.